|
Jun 14
|
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
|
|
May 22
|
We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth
|
|
May 15
|
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 13
|
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
|
|
Mar 23
|
Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway
|
|
Mar 21
|
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
|
Mar 20
|
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
|
|
Mar 8
|
Jim Cramer’s 10 Latest Stock Picks This Week
|
|
Jan 9
|
Are Investors Undervaluing Cabaletta Bio, Inc. (NASDAQ:CABA) By 47%?
|
|
Dec 19
|
Cabaletta Bio Stock (NASDAQ:CABA): Analysts Expect More Gains Despite Massive Rally
|
|
Nov 28
|
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
|
|
Nov 6
|
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
|
|
Nov 6
|
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
|
|
Sep 19
|
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
|
|
Sep 1
|
Top Growth Stocks for September 2023
|
|
Sep 1
|
Top Stocks for September 2023
|
|
Aug 31
|
Wall Street Analysts Believe Cabaletta Bio, Inc. (CABA) Could Rally 41.61%: Here's is How to Trade
|
|
Aug 30
|
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September
|
|
Aug 10
|
Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
|